Secondary end points at 1, 3 and 5 years
| At 1 year | At 3 years | At 5 years | |||||||
| TAVR N (%) | SAVR N (%) | HR (95% CI) | TAVR N (%) | SAVR N (%) | HR (95% CI) | TAVR N (%) | SAVR N (%) | HR (95% CI) | |
| Ischaemic stroke | 60 (2.35) | 107 (1.17) | 1.07 (0.71 to 1.61) | 110 (4.31) | 228 (2.48) | 1.30 (0.97 to 1.74) | 120 (4.70) | 320 (3.49) | 1.17 (0.90 to 1.53) |
| Haemorrhagic stroke | 18 (0.71) | 38 (0.41) | 1.06 (0.53 to 2.10) | 27 (1.06) | 67 (0.73) | 1.10 (0.63 to 1.95) | <33* (<1.28) | 87 (0.95) | 1.14 (0.67 to 1.94) |
| MI | 121 (4.74) | 120 (1.31) | 1.77 (1.26 to 2.50) | 230 (9.02) | 258 (2.81) | 1.92 (1.51 to 2.43) | 265 (10.39) | 358 (3.90) | 1.96 (1.58 to 2.42) |
| Incident AF | 93 (3.65) | 348 (3.79) | 0.73 (0.54 to 0.98) | 171 (6.70) | 468 (5.10) | 1.05 (0.83 to 1.33) | 198 (7.76) | 567 (6.18) | 1.14 (0.92 to 1.42) |
| Endocarditis | 64 (2.51) | 207 (2.25) | 1.07 (0.75 to 1.54) | 100 (3.92) | 315 (3.43) | 1.23 (0.92 to 1.65) | 111 (4.35) | 395 (4.30) | 1.16 (0.89 to 1.52) |
| Reintervention, any | 15 (0.59) | 54 (0.59) | 2.00 (0.97 to 4.16) | <20* (<0.78) | 97 (1.06) | 1.73 (0.96 to 3.11) | <25* (<0.90) | 141 (1.54) | 1.64 (0.93 to 2.89) |
| Complication (valve) | 74 (2.90) | 207 (2.25) | 1.40 (0.98 to 2.00) | 113 (4.43) | 335 (3.65) | 1.35 (1.02 to 1.79) | 122 (4.78) | 448 (4.88) | 1.25 (0.96 to 1.62) |
| AKI | 21 (0.82) | 42 (0.46) | 1.65 (0.80 to 3.40) | 27 (1.06) | 73 (0.80) | 1.53 (0.85 to 2.76) | <33* (<1.28) | 96 (1.05) | 1.41 (0.83 to 2.39) |
| Pacemaker | 47 (1.84) | 91 (0.99) | 0.99 (0.64 to 1.54) | 74 (2.90) | 168 (1.83) | 1.11 (0.79 to 1.56) | 88 (3.45) | 218 (2.37) | 1.32 (0.95 to 1.83) |
| Defibrillator | <10* (<0.03) | 12 (0.13) | 0.94 (0.22 to 4.03) | <10* (<0.03) | 22 (0.24) | 1.99 (0.70 to 5.71) | <10* (<0.03) | 28 (0.30) | 1.74 (0.66 to 4.58) |
| Readmission | 1808 (70.87) | 5330 (58.05) | 0.89 (0.82 to 0.95) | 2182 (85.54) | 6915 (75.31) | 0.95 (0.89 to 1.01) | 2237 (87.69) | 7473 (81.39) | 0.96 (0.90 to 1.02) |
| CHF readmission | 354 (13.88) | 577 (6.28) | 0.87 (0.73 to 1.03) | 528 (20.70) | 779 (8.48) | 1.18 (1.02 to 1.37) | 589 (23.09) | 987 (10.75) | 1.28 (1.11 to 1.46) |
| Angina readmission | 59 (2.31) | 64 (0.70) | 1.93 (1.21 to 3.10) | 124 (4.86) | 158 (1.72) | 1.86 (1.37 to 2.54) | 134 (5.25) | 213 (2.32) | 1.86 (1.39 to 2.48) |
| Admission to nursing home | 94 (3.68) | 99 (1.08) | 0.89 (0.62 to 1.26) | 189 (7.41) | 203 (2.21) | 1.16 (0.90 to 1.48) | 231 (9.06) | 299 (3.26) | 1.25 (1.00 to 1.56) |
| Admission to chronic care | 124 (4.86) | 168 (1.83) | 0.88 (0.65 to 1.17) | 197 (7.72) | 281 (3.06) | 0.97 (0.77 to 1.23) | 234 (9.17) | 375 (4.08) | 1.09 (0.88 to 1.35) |
| Admission to nursing home or chronic care | 199 (7.80) | 245 (2.67) | 0.88 (0.69 to 1.11) | 341 (13.37) | 436 (4.75) | 1.04 (0.87 to 1.24) | 415 (16.27) | 601 (6.55) | 1.17 (0.99 to 1.38) |
Competing risk model reporting subdistribution HR and 95% CI of secondary outcomes occurring from date of discharge to 1, 3 and 5 years for patients undergoing TAVR versus SAVR.
*Data were suppressed due to ICES reporting policy regarding small cell (the number of events is equal to or less than 5).
AF, atrial fibrillation; AKI, acute kidney injury; CHF, chronic heart failure; ICES, Institute for Clinical Evaluative Sciences ; MI, myocardial infarction; N, the number of events; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.